suptavumab
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss
Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss
Regeneron’s New Drug Application for cemdisiran accepted for review by FDA and EMA
Globally, around 150 to 200 out of every million people have myasthenia gravis
Regeneron agrees research collaboration with Parabilis Medicines
Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties
Study shows infants given RSV vaccination benefit beyond first RSV season
The RSV virus is highly contagious and can cause serious respiratory illness for infants
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
Regeneron’s Libtayo receives EC approval for skin cancer
Phase 3 trial results showed the drug significantly improved disease-free survival
Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition
The deal includes an early-stage combination vaccine candidate for RSV and hMPV
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease
Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults
The vaccine is already approved in the US for use in adults aged 60 years and older
Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones
These are the first clinical study results for the drug in a large population of patients with darker skin tones
Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants
Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight